Unichem gets USFDA approval to sell prostate drug
New Delhi: Drug firm Unichem Laboratories has received approval from the US health regulator to market alfuzosin hydrochloride extended release tablets, used in treating prostatic hyperlasia, in the American market.The company has received final approval from the US Food and Drug Administration (USFDA) for alfuzosin hydrochloride extended release tablets, a generic version of...
Login or Register to read the full article
New Delhi: Drug firm Unichem Laboratories has received approval from the US health regulator to market alfuzosin hydrochloride extended release tablets, used in treating prostatic hyperlasia, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) for alfuzosin hydrochloride extended release tablets, a generic version of Concordia Pharmaceuticals Ins's Uroxatral extended release tablets, Unichem Laboratories said in a regulatory filing.
The tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperlasia in adults.
"The product will be commercialised from Unichem's Goa plant. The active pharmaceutical ingredients (API) for the product would also be made in-house at Pithampur plant," the company said.
Unichem now has a total of 20 abbreviated new drug application (ANDA) approvals from the USFDA.
The company has received final approval from the US Food and Drug Administration (USFDA) for alfuzosin hydrochloride extended release tablets, a generic version of Concordia Pharmaceuticals Ins's Uroxatral extended release tablets, Unichem Laboratories said in a regulatory filing.
The tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperlasia in adults.
"The product will be commercialised from Unichem's Goa plant. The active pharmaceutical ingredients (API) for the product would also be made in-house at Pithampur plant," the company said.
Unichem now has a total of 20 abbreviated new drug application (ANDA) approvals from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd